Product Description: Resolvin D1 (RvD1), an endogenous pro-resolving mediator of inflammation, is derived from omega-3 docosahexaenoic acid during the resolution phase of acute inflammation. Resolvin D1 blocks proinflammatory neutrophil migration by regulating actin polymerization, reduces TNF-α–mediated inflammation in macrophages, and enhances phagocytosis of apoptotic cells by macrophages[1][2].
Applications: COVID-19-immunoregulation
Formula: C22H32O5
References: [1]Schmid M, et al. Resolvin D1 Polarizes Primary Human Macrophages toward a Proresolution Phenotype through GPR32. J Immunol. 2016 Apr 15;196(8):3429-37./[2]Gao Y, et al. Resolvin D1 Improves the Resolution of Inflammation via Activating NF-κB p50/p50-Mediated Cyclooxygenase-2 Expression in Acute Respiratory Distress Syndrome. J Immunol. 2017 Aug 9. pii: ji1700315./[3]Benabdoun HA, et al. In vitro and in vivo assessment of the proresolutive and antiresorptive actions of resolvin D1: relevance to arthritis. Arthritis Res Ther. 2019 Mar 12;21(1):72.
CAS Number: 872993-05-0
Molecular Weight: 376.49
Compound Purity: 99.60
Research Area: Inflammation/Immunology
Solubility: 10 mM in DMSO
Target: Endogenous Metabolite
Deutsch
English
